Burrill Report: Biotech Innovation Gets the Cash
If the past week is any indication, big pharma is showing that it is willing to pay for biotech innovation.
feature1
NicOx Reports Positive Data for Cholesterol Drug
NicOx announced that NCX 6560, its drug candidate for high cholesterol, met its primary and secondary endpoints in a Phase Ib man-in study.
ProtoxPresents Data, Awaits Key Results for PRX302
Protox Therapeutics applies genetic engineering techniques to create innovative, targeted protein-based therapeutics which are focused on prostate conditions and cancer.
Unilife: Medical Device Innovator Creating Jobs in PA
Unilife Medical Solutions is an emerging medical device manufacturer with business segments that include pre-filled syringes for pharmaceutical companies to deliver injectable medications, sharps safety devices for healthcare facilities, and contract manufacturing of medical devices.
FDA Calendar November Stocks: Turkeys or a Happy Thanksgiving?
On 10/19/09, BioElectronics (OTC: BIEL.PK) announced the initial results from the pilot section of its ongoing acetaminophen comparison study.
OneMedPlace and OneMedForum Enter a Strategic Partnership with MarketWire
OneMedPlace has entered into a partnership with Marketwire, a full-service newswire and communications workflow solutions provider for public relations, investor relations and marketing communications professionals, to accomplish the company’s media outreach goals.
Interview with Jeffrey Davis, CEO of Access Pharmaceuticals
OneMedPlace recently interviewed CEO Jeffrey Davis about the Dallas-based company’s pipeline.
BioDelivery Sciences (NASDAQ: BDSI): Restarting the Catalyst Cycle
BDSI focuses on the niche market of pain management and supportive cancer care.
DATATRAK: Low Valuation, Improving Results
DATATRAK International Inc. (OTC: DATA.PK) is a clinical trials information technology (IT) and services company that is focused on increasing its share of an estimated $720 million (M) Electronic Data Capture (EDC) market opportunity.
Inovio Biomedical (AMEX: INO): A DNA Vaccine Delivery Innovator
Inovio Biomedical (AMEX: INO) is developing a robust pre-clinical and early clinical stage pipeline of innovative DNA-based vaccines and therapeutics that target cancer, influenza, and other infectious diseases (e.g. HIV) based on its SynCon DNA vaccine construct and electroporation DNA delivery technology platforms.